ORIC Pharmaceuticals Inc. (ORIC)
9.90
1.30 (15.12%)
At close: Jan 14, 2025, 3:59 PM
9.90
0.00%
After-hours Jan 14, 2025, 07:52 PM EST
undefined% (undefined)
| Bid | 8.5 |
| Market Cap | 698.61M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.82 |
| PE Ratio (ttm) | -5.44 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.99 |
| Volume | 1,102,859 |
| Avg. Volume (20D) | 437,977 |
| Open | 8.82 |
| Previous Close | 8.60 |
| Day's Range | 8.82 - 10.05 |
| 52-Week Range | 6.33 - 16.65 |
| Beta | undefined |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 112
Stock Exchange NASDAQ
Ticker Symbol ORIC
Website https://www.oricpharma.com
Analyst Forecast
According to 9 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 91.92% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-0.42%
Oric Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago ·
Source
+1.26%
Oric Pharmaceuticals shares are trading higher after the company announced it presented a poster highlighting certain best-in-class properties of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
